Sonlicromanol

• CAT Number: I007499
• CAS Number: 1541170-75-5
• Molecular Formula: C19H28N2O3
• Molecular Weight: 332.44
• Purity: ≥95%
• Synonyms: (2S)-6-hydroxy-2,5,7,8-tetramethyl-N-[(3R)-piperidin-3-yl]-3,4-dihydrochromene-2-carboxamide
• InChI: InChI=1S/C19H28N2O3/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14/h14,20,22H,5-10H2,1-4H3,(H,21,23)/t14-,19+/m1/s1
• InChIKey: LZYWLEPSQNXESC-KUHUBIRLSA-N
• SMILES: CC1=C(C2=C(CCC(O2)(C)C(=O)NC3CCCNC3)C(=C1O)C)C

Sonlicromanol (Cat No.: I007499) is a small-molecule drug candidate developed for the treatment of mitochondrial diseases and other disorders linked to oxidative stress. It acts as a redox-modulating agent, balancing cellular reactive oxygen species (ROS) while preserving essential signaling functions. By improving mitochondrial function and reducing oxidative damage, Sonlicromanol shows promise in conditions such as Leigh disease, Friedreich’s ataxia, and other rare metabolic disorders. Currently under clinical investigation, it represents a novel therapeutic approach targeting mitochondrial dysfunction and redox imbalance.

Reference

[1]. X Jiang, et al. Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE 2 biosynthesis by sonlicromanol’s metabolite KH176m. Sci Rep. 2021 Jan 13;11(1):880.
[Content Brief]

[2]. Zikai Feng, et al. Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones. Pharmaceuticals (Basel). 2020 Aug 7;13(8):184.
[Content Brief]

[3]. Sanne J C M Frambach, et al. Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165727.
[Content Brief]